News

Molecules from the venom of one of the world’s largest spiders could help a team of Institute for Molecular Bioscience-led researchers tailor pain blockers for people with irritable bowel syndrome (IBS).

A recent study published in the journal Nature Medicine describes a new Dual CAR T cell immunotherapy that can help fight HIV infection.

Using information from the Swedish public health agency, researchers determined that BCG vaccination during infancy actually does not protect against the SARS-CoV-2 virus.

New research has uncovered the presence of CD19 -- a B cell molecule targeted by chimeric antigen receptor (CAR) T cell immunotherapy to treat leukemia, lymphoma, and multiple myeloma -- in brain cells that protect the blood brain barrier (BBB).

Researchers report novel findings concerning the therapeutic mechanisms of pomalidomide. They showed that pomalidomide causes the breakdown of a protein called ARID2. ARID2 promotes the "expression" of genes that are critical for the growth of multiple myeloma cells, so breaking down ARID2 is harmful to the cancer cells and beneficial to patients.

In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefit.

Researchers at EPFL have developed remote-controlled, mechanical microdevices that, when inserted into human tissue, can manipulate the fluid that surrounds them, collect cells or release drugs. This breakthrough offers numerous potential applications in the biomedical field, from diagnostics to therapy.

Scientists have identified a new drug that could prevent or mitigate the consequences derived from SARS-CoV-2 infection.

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to trial results.

Results from the PROfound trial have showed that olaparib – a drug called a PARP inhibitor – can be used successfully to treat prostate cancers with a "weakness" in their ability to repair damaged DNA.